az értekezés - Semmelweis Egyetem Doktori Iskola

86. Thompson PI, Joel SP, John L, Wedzicha JA, Maclean M, Slevin ML. (1995)
Respiratory depression following morphine and morphine-6-glucuronide in normal
subjects. Br J Clin Pharmacol 40 (2): 145-152.
87. Guan Y, Johanek LM, Hartke TV, Shim B, Tao Y-X, Ringkamp M, Meyer RA, Raja
SN. (2008) Peripherally acting mu-opioid receptor agonist attenuates neuropathic pain
in rats after L5 spinal nerve injury. Pain 138 (2): 318-329.
88. Hernández L, Romero A, Almela P, García-Nogales P, Laorden ML, Puig MM. (2009)
Tolerance to the antinociceptive effects of peripherally administered opioids:
Expression of [beta]-arrestins. Brain Res 1248: 31-39.
89. Obara I, Parkitna JR, Korostynski M, Makuch W, Kaminska D, Przewlocka B,
Przewlocki R. (2009) Local peripheral opioid effects and expression of opioid genes in
the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141
(3): 283-291.
90. Smith HS. (2008) Peripherally-acting opioids. Pain Physician 11 (SPEC. ISS. 2): S121-
S132
91. Zheng W. (2010) Activation of mu opioid receptor inhibits the excitatory glutamatergic
transmission in the anterior cingulate cortex of the rats with peripheral inflammation.
Eur J Pharmacol 628 (1-3): 91-95.
92. Wittwer E, Kern SE. (2006) Role of morphine's metabolites in analgesia: Concepts and
controversies. AAPS J 8 (2): E348-E352.
93. Lotsch J. (2004) Morphine metabolites as novel analgesic drugs? Curr Opin
Anaesthesiol 17 (5): 449-453.
94. Lotsch J, Geisslinger G. (2001) Morphine-6-glucuronide: an analgesic of the future?
Clin Pharmacokinet 40 (7): 485-499.
95. Preechagoon D, Brereton I, Staatz C, Prankerd R. (1998) Ester prodrugs of a potent
analgesic, morphine-6-sulfate: syntheses, spectroscopic and physicochemical
properties. Int J Pharm 163 (1-2): 177-190.
96. Preechagoon D, Smith MT, Prankerd RJ. (1998) Investigation of the antinociceptive
efficacy and relative potency of extended duration injectable. Int J Pharm 163 (1): 191-
201.
96